INVESTORS & MEDIA
Corporate Governance
| Date | Name | Title | Filing | Type | Shares Traded | Price | Total Held |
|---|---|---|---|---|---|---|---|
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 628
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 14,922 | $16.42 | 588,235 |
| Dec 31, 2003 |
Director
Trans History: 742
|
Director | Form 5 | Bona fide gift | 14,786 | $15.10 | 588,485 |
| Dec 16, 2008 |
Director, EVP, CSO, & Pres Regn Res Labs
Trans History: 628
|
Director, EVP, CSO, & Pres Regn Res Labs | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 26,991 | $7.41 | 590,085 |
| Feb 10, 2017 |
Director, President & CSO
Trans History: 628
|
Director, President & CSO | Form 5 | Other acquisition or disposition | -- | -- | 591,348 |
| Dec 15, 2016 |
Director, President Regeneron Laboratori
Trans History: 628
|
Director, President Regeneron Laboratori | Form 4 | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | 95,223 | $380.09 | 591,348 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 10,023 | $467.53 | 591,569 |
| Aug 06, 2021 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 160,000 | $52.03 | 596,176 |
| May 12, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Open market or private sale of non-derivative or derivative security | 5,810 | $566.51 | 596,620 |
| May 11, 2020 |
Director, President & CEO
Trans History: 404
|
Director, President & CEO | Form 4 | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 | 125,000 | $30.63 | 599,499 |
| Mar 10, 2020 |
Director, President and Chief Scientific
Trans History: 628
|
Director, President and Chief Scientific | Form 4 | Open market or private sale of non-derivative or derivative security | 11,916 | $466.58 | 601,592 |
* Represents the number of non-derivative securities directly held. (I) Indicates that some (or all) of these shares are held indirectly.